Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GNC Q3 results

This article was originally published in The Tan Sheet

Executive Summary

Gains in sales of sports nutrition, herbs and vitamin products offset a 32.4% decline in the diet category for the quarter, the Pittsburgh-based company states during a third-quarter earnings call Nov. 3. GNC posted a slight decrease of 0.2% in consolidated revenues for the third quarter with $322.6 mil. versus $323.1 mil. for the same period in 2004. The diet segment will continue to decline for another six months, but hopefully will take an upturn as new innovations in weight management and energy increase sales for the category, CFO Curt Larrimer predicts. "I think that as the business turns sometime in 2006 that GNC is positioned to be the market leader in this category once again," he adds. Net income for the quarter was $3.2 mil. compared to $8.5 mil. during the prior-year period...

You may also be interested in...

GNC Eyes Possible IPO, Reports 14% Revenue Growth

GNC Corp. reported a 14% increase in third-quarter revenues to $367.7 mil., but the nutritional supplement chain's parent holding company said it is considering selling GNC or conducting an initial public offering to increase its value to investors

Nearly One Year Post-Celgene: BMS CMO On Pipeline Progress, Clinical Trial Diversity

Chief medical officer Samit Hirawat outlines R&D successes – though there have been some setbacks since it bought Celgene for $74bn last year – and the company’s commitment to clinical trial diversity.

Lilly’s 340B Restrictions: Jury Is Still Out On Appropriateness, But Optics Are Bad, HHS Says

Letter from department’s general counsel responds to request from the company for a pre-enforcement advisory opinion. Despite the letter, Lilly maintains its ‘limited distribution program is fully consistent with applicable laws and regulations.’





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts